Vendors are feeling the economic impact of dwindling COVID-related bioproduction, but Thermo Fisher and Danaher remain unfazed, the firms said at JPM 2023. Many bioprocess vendors reported falling orders in the latter half of 2022 as biopharma reduced stock orders for vaccine and therapeutics following two years of unprecedented pandemic-related growth. This bioprocess destocking dynamic – described by some as a “swift normalization of demand” – was brought up at this week’s JP Morgan Healthcare Conference in San Francisco but…
